This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Joanne Kim Biography and Net Worth

CFO of BioVie

Presently, Joanne Wendy Kim occupies the position of Chief Financial Officer & Secretary at BioVie, Inc.

In her past career she occupied the position of Chief Financial Officer for Landmark Education Enterprises, Inc., Senior Manager at KPMG LLP and Director-National Office Sec Department at BDO USA LLP.

She received an undergraduate degree from The California State University.

How old is Joanne Wendy Kim?: Ms. Kim is currently 69 years old. There are 5 older executives and no younger executives at BioVie. The oldest executive at BioVie is Dr. Christopher L. Reading Ph.D., Senior Vice President of Alzheimer's Disease Program, who is 76 years old. Learn More on Joanne Wendy Kim's age.
How do I contact Joanne Wendy Kim?: The corporate mailing address for Ms. Kim and other BioVie executives is , , . BioVie can also be reached via phone at (775) 888-3162 and via email at [email protected]. Learn More on Joanne Wendy Kim's contact information.
Has Joanne Wendy Kim been buying or selling shares of BioVie?: Joanne Wendy Kim has not been actively trading shares of BioVie during the last ninety days. Most recently, on Tuesday, December 7th, Joanne Wendy Kim bought 2,000 shares of BioVie stock. The stock was acquired at an average cost of $5.40 per share, with a total value of $10,800.00. Learn More on Joanne Wendy Kim's trading history.

Joanne Wendy Kim Insider Trading History at BioVie

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/7/2021	Buy	2,000	$5.40	$10,800.00

Joanne Wendy Kim Buying and Selling Activity at BioVie

BioVie Company Overview

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Today's Range

Now: $1.90

$1.90

$2.13

50 Day Range

MA: $2.67

$1.10

$3.51

2 Week Range

Now: $1.90

$1.04

$33.10

Volume

1,452,870 shs

Average Volume

1,679,768 shs

Market Capitalization

$33.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4